HK Stock Market Move | AIM VACCINE (06660) rose more than 14% in intraday trading. Institutions predict that the company will see a revaluation in value this year, and its core products will become more stable.

AIM VACCINE (06660) rose over 14% during trading hours, and as of the time of writing, it was up 13.75% at 5.79 Hong Kong dollars, with a turnover of 17.5664 million Hong Kong dollars. On the news front, FOSUN INTL Securities issued a research report, covering AIM VACCINE for the first time and pointing out that due to the company's strong product pipeline, technical leadership, and international growth potential, they have given the stock a "Buy" rating with a 12-month target price of 11.0 Hong Kong dollars. The report mentioned that as a leading full-industry-chain vaccine company in China, AIM VACCINE has strong research and development, manufacturing, and commercialization capabilities. FOSUN INTL Securities predicts that by 2025, the company's core products (hepatitis B vaccine and rabies vaccine) will become stable, while iterative blockbuster vaccines, such as serum-free rabies vaccine, PCV13, MCV4, mRNA respiratory syncytial virus vaccine, and mRNA herpes zoster vaccine, will drive transformative growth (expected compound annual revenue growth rate from 2024-2027 is 47%, achieving breakeven in 2025, and net profit reaching 1.52 billion Chinese yuan in 2027). FOSUN INTL Securities added that although market sentiment tends to focus on concerns about internal competition and pricing challenges in the Chinese vaccine industry, their view is more optimistic. They believe that AIM VACCINE, with its diversified product portfolio, technological advantages, and global expansion strategy, presents an attractive investment opportunity for investors. With a series of high-value products set to be launched soon and profitability expected to rebound from 2025 onwards, the company is poised for strong growth and possible revaluation.